BIOMAT Database Logo BIOMAT Database Logo

Omalizumab: a treatment for severe asthma in real life? 2015

Anaïs Briquet, and Pascal Chanez
Département des Maladies Respiratoires, AP-HM, INSERM CNRS U 1067, UMR7733, Aix Marseille Université, Marseille, France.

UI MeSH Term Description Entries
D008297 Male Males
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069444 Omalizumab An anti-IgE, recombinant, humanized monoclonal antibody which specifically binds to the C epsilon3 domain of IMMUNOGLOBULIN E, the site of high-affinity IgE receptor binding. It inhibits the binding of IgE to MAST CELLS and BASOPHILS to reduce the severity of the allergic response and is used in the management of persistent allergic ASTHMA. Xolair
D001249 Asthma A form of bronchial disorder with three distinct components: airway hyper-responsiveness (RESPIRATORY HYPERSENSITIVITY), airway INFLAMMATION, and intermittent AIRWAY OBSTRUCTION. It is characterized by spasmodic contraction of airway smooth muscle, WHEEZING, and dyspnea (DYSPNEA, PAROXYSMAL). Asthma, Bronchial,Bronchial Asthma,Asthmas
D018927 Anti-Asthmatic Agents Drugs that are used to treat asthma. Anti-Asthmatic,Anti-Asthmatic Agent,Anti-Asthmatic Drug,Antiasthmatic,Antiasthmatic Agent,Antiasthmatic Drug,Anti-Asthmatic Drugs,Anti-Asthmatics,Antiasthmatic Agents,Antiasthmatic Drugs,Antiasthmatics,Agent, Anti-Asthmatic,Agent, Antiasthmatic,Agents, Anti-Asthmatic,Agents, Antiasthmatic,Anti Asthmatic,Anti Asthmatic Agent,Anti Asthmatic Agents,Anti Asthmatic Drug,Anti Asthmatic Drugs,Anti Asthmatics,Drug, Anti-Asthmatic,Drug, Antiasthmatic,Drugs, Anti-Asthmatic,Drugs, Antiasthmatic

Related Publications

Anaïs Briquet, and Pascal Chanez
Can omalizumab be an alternative treatment for non-atopic severe asthma? A real-life experience with omalizumab.
March 2023, Tuberkuloz ve toraks,
Anaïs Briquet, and Pascal Chanez
Effectiveness of omalizumab in severe persistent asthma under real-life conditions.
July 2014, Canadian family physician Medecin de famille canadien,
Anaïs Briquet, and Pascal Chanez
Duration of the efficacy of omalizumab after treatment discontinuation in 'real life' severe asthma.
August 2018, Thorax,
Anaïs Briquet, and Pascal Chanez
Response to omalizumab in patients with severe allergic asthma: A real-life study.
October 2017, Respiratory medicine,
Anaïs Briquet, and Pascal Chanez
Real-world effectiveness of omalizumab for severe allergic asthma treatment in Colombia.
November 2022, BMC pulmonary medicine,
Anaïs Briquet, and Pascal Chanez
Real-life study in non-atopic severe asthma patients achieving disease control by omalizumab treatment.
June 2021, Allergy,
Anaïs Briquet, and Pascal Chanez
Long-term omalizumab treatment in severe allergic asthma: the South-Eastern Mediterranean "real-life" experience.
February 2012, Pulmonary pharmacology & therapeutics,
Anaïs Briquet, and Pascal Chanez
Omalizumab in Children with Severe Allergic Asthma: The Italian Real-Life Experience.
March 2017, Current respiratory medicine reviews,
Anaïs Briquet, and Pascal Chanez
Real-life long-term omalizumab therapy in children with severe allergic asthma.
September 2015, The European respiratory journal,
Anaïs Briquet, and Pascal Chanez
Cost-effectiveness of omalizumab in severe persistent asthma in Spain: a real-life perspective.
March 2015, The Journal of asthma : official journal of the Association for the Care of Asthma,
Copied contents to your clipboard!